(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
3 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 7.63%
@ $43.42
発行日: 8 4月 2024 @ 22:30
リターン: -4.20%
前回のシグナル: 4月 5 - 01:17
前回のシグナル:
リターン: 0.06 %
Live Chart Being Loaded With Signals
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy...
Stats | |
---|---|
本日の出来高 | 540 395 |
平均出来高 | 1.07M |
時価総額 | 6.06B |
EPS | $0 ( 2024-02-21 ) |
次の収益日 | ( $-1.070 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -16.25 |
ATR14 | $0.0240 (0.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Baroldi Joseph | Sell | 10 838 | Restricted Stock Unit |
2024-04-15 | Baroldi Joseph | Buy | 10 838 | Common Stock |
2024-04-16 | Baroldi Joseph | Sell | 4 006 | Common Stock |
2024-04-15 | Birchler Brian | Buy | 1 875 | Common Stock |
2024-04-16 | Birchler Brian | Sell | 905 | Common Stock |
INSIDER POWER |
---|
45.60 |
Last 100 transactions |
Buy: 1 051 999 | Sell: 391 277 |
ボリューム 相関
Ionis Pharmaceuticals Inc 相関
10 最も負の相関 | |
---|---|
STAY | -0.908 |
TRMD | -0.878 |
BCOR | -0.875 |
PAYA | -0.873 |
IBEX | -0.868 |
PDFS | -0.867 |
BNIXU | -0.866 |
TGLS | -0.865 |
LRFC | -0.865 |
ARDX | -0.861 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Ionis Pharmaceuticals Inc 相関 - 通貨/商品
Ionis Pharmaceuticals Inc 財務諸表
Annual | 2023 |
収益: | $787.65M |
総利益: | $778.51M (98.84 %) |
EPS: | $-2.56 |
FY | 2023 |
収益: | $787.65M |
総利益: | $778.51M (98.84 %) |
EPS: | $-2.56 |
FY | 2022 |
収益: | $587.00M |
総利益: | $573.00M (97.61 %) |
EPS: | $-1.900 |
FY | 2021 |
収益: | $810.46M |
総利益: | $799.61M (98.66 %) |
EPS: | $-0.200 |
Financial Reports:
No articles found.
Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。